GO:1905091 positive regulation of type 2 mitophagy: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1905091 describes any process that activates or increases the frequency, rate or extent of type 2 mitophagy, the PRKN/PINK1-dependent clearance of depolarized mitochondria.
• Type 2 mitophagy is triggered when mitochondrial membrane potential is lost, allowing PINK1 to accumulate on the outer membrane and recruit PRKN to ubiquitinate mitochondrial proteins.
• Positive regulators of this pathway include PINK1, PRKN, NIPA2, and BNIP3-dependent signaling components that respond to metabolic and oxidative stress [1,5,8].
• Dysregulation of type 2 mitophagy contributes to diabetic cardiomyopathy, periodontitis-associated bone loss, Parkinson's disease, and type 2 diabetes osteoporosis [1,3,4,8].
• Experimental dissection of GO:1905091 requires combining live-cell imaging of mitophagy reporters with CRISPR knockout, point-mutation, and knock-in models [1,3,8].
• The pathway is pharmacologically tractable: metformin, ginsenoside Rg3, and mitochondrial biogenesis modulators can influence mitophagic flux [2,4,6].
Description
Type 2 mitophagy, also known as PRKN-mediated or parkin-mediated mitophagy, is a selective autophagic process that removes damaged mitochondria in response to mitochondrial depolarization. The Gene Ontology term GO:1905091, positive regulation of type 2 mitophagy, captures any molecular event that activates or increases the frequency, rate or extent of this clearance pathway. Because mitochondria are central to energy production, calcium buffering, and apoptosis, their quality control is essential for cellular homeostasis, and failure of type 2 mitophagy is increasingly linked to human disease [3,8]. Researchers study GO:1905091 to understand how cells sense mitochondrial damage and how this response can be therapeutically modulated in neurodegeneration, metabolic disease, and inflammatory bone disorders [1,4,8]. The pathway is experimentally accessible through fluorescent mitophagy reporters, ubiquitin profiling, and genetic perturbation of PINK1-PRKN signaling [1,3].
positive regulation of type 2 mitophagy At A Glance
| GO ID | GO:1905091 |
|---|---|
| GO term | positive regulation of type 2 mitophagy |
| Ontology | biological_process |
| Synonym | activation of parkin-mediated mitophagy in response to mitochondrial depolarization; positive regulation of PRKN-mediated stimulation of mitophagy in response to mitochondrial depolarization |
| Major function | Increases the rate of PINK1-PRKN-dependent clearance of depolarized mitochondria |
| Upstream trigger | Loss of mitochondrial membrane potential and PINK1 stabilization on the outer mitochondrial membrane |
| Key effectors | PINK1, PRKN, NIPA2, BNIP3, and downstream autophagy receptors |
| Associated diseases | Parkinson's disease, diabetic cardiomyopathy, periodontitis-induced bone loss, type 2 diabetes osteoporosis |
| Research methods | Mitophagy reporters, CRISPR knockout/knock-in, live-cell imaging, ubiquitin proteomics |
What Is GO:1905091?
GO:1905091 is a biological process term defined as any process that activates or increases the frequency, rate or extent of type 2 mitophagy. In practice, this means the positive regulation of the PINK1-PRKN-dependent autophagic removal of mitochondria that have lost membrane potential. The term is synonymous with activation of parkin-mediated mitophagy in response to mitochondrial depolarization and with positive regulation of PRKN-mediated stimulation of mitophagy in response to mitochondrial depolarization.
Why Is positive regulation of type 2 mitophagy Important in Cell Biology?
Positive regulation of type 2 mitophagy is important because it determines whether cells successfully eliminate damaged mitochondria or accumulate dysfunctional organelles that drive oxidative stress, inflammation, and cell death [1,3]. In cardiac tissue, maintaining mitophagic flux is essential for cardiac function during high-fat-diet-induced diabetic cardiomyopathy. In bone, impaired mitophagy in osteoclasts and osteoblasts contributes to periodontitis-induced bone loss and type 2 diabetes osteoporosis [1,8]. In the brain, restoration of mitochondrial cardiolipin homeostasis and mitophagy protects against Parkinson's disease pathology. Thus, understanding GO:1905091 provides mechanistic insight into diverse diseases and identifies druggable nodes for therapeutic intervention [2,4,6].
• Maintains mitochondrial quality control by removing depolarized mitochondria before they release pro-apoptotic factors.
• Protects cardiac function under metabolic stress such as high-fat-diet-induced diabetic cardiomyopathy.
• Restrains periodontitis-induced bone loss by preventing osteoclast mitophagy impairment.
• Supports osteoblast function and bone homeostasis in type 2 diabetes osteoporosis.
• Contributes to neuronal survival and is dysregulated in Parkinson's disease.
• Is required for odontoblastic differentiation of dental pulp stem cells through BNIP3-dependent mitophagy.
• Can be pharmacologically modulated by metformin and ginsenoside Rg3 [4,6].
• Serves as a mechanistic link between ferroptosis and pyroptosis in disease networks.
• Provides a tractable target for CRISPR-based functional genomics of mitochondrial quality control [1,3,8].
• Underpins mitochondrial biogenesis and turnover balance in metabolic tissues.
What Happens During positive regulation of type 2 mitophagy?
Mitochondrial depolarization and PINK1 stabilization
In simple terms: When a mitochondrion loses its electrical charge, a sensor protein called PINK1 sticks to its surface and starts the cleanup signal.
The initiating event in type 2 mitophagy is the loss of mitochondrial membrane potential, which prevents PINK1 from being imported and degraded, allowing it to accumulate on the outer mitochondrial membrane. This stabilization is the first committed step that positive regulators of GO:1905091 act upon, and it is required for downstream PRKN recruitment.
PRKN recruitment and ubiquitination
In simple terms: PINK1 flags the damaged mitochondrion by activating parkin, which then attaches ubiquitin tags to mitochondrial proteins.
PINK1 phosphorylates ubiquitin and PRKN, leading to PRKN activation and its recruitment to the mitochondrial surface. Activated PRKN ubiquitinates outer membrane proteins, generating a ubiquitin coat that is recognized by autophagy receptors. Positive regulation of type 2 mitophagy therefore includes events that enhance PRKN activation, recruitment, or catalytic output.
Autophagosome formation and cargo recognition
In simple terms: The ubiquitin tags attract the cell's recycling machinery, which wraps the damaged mitochondrion in a membrane bubble.
Ubiquitinated mitochondria are engaged by autophagy receptors that link the cargo to LC3 on nascent autophagosomes. BNIP3-dependent signaling can also contribute to mitophagy under specific conditions, as shown in odontoblastic differentiation. Positive regulators of GO:1905091 increase the efficiency of this cargo recognition and autophagosome formation step [1,5].
Lysosomal fusion and mitochondrial clearance
In simple terms: The membrane bubble carrying the damaged mitochondrion fuses with a lysosome, where the mitochondrion is digested.
The final stage of type 2 mitophagy is the fusion of autophagosomes with lysosomes and the degradation of mitochondrial contents. Positive regulation of this process increases the frequency or rate of clearance, restoring mitochondrial network quality [1,3]. Impaired lysosomal fusion leads to accumulation of damaged mitochondria and cellular dysfunction.
Integration with cellular stress responses
In simple terms: The cleanup process is tuned by the cell's overall stress and metabolic state.
Positive regulation of type 2 mitophagy is coordinated with mitochondrial biogenesis and metabolic signaling, as reviewed for pharmacological approaches to mitochondrial turnover. In disease contexts such as diabetic cardiomyopathy, high-fat diet alters mitophagic flux and cardiac function. Crosstalk with ferroptosis and pyroptosis pathways further positions type 2 mitophagy within a broader stress-response network.
Key Genes Involved in GO:1905091 positive regulation of type 2 mitophagy
The following genes and proteins are experimentally implicated in the positive regulation of type 2 mitophagy or in the type 2 mitophagy pathway it controls.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PINK1 | Stabilizes on depolarized mitochondria and activates PRKN | Core initiator of type 2 mitophagy; knockout models abolish pathway |
| PRKN | Ubiquitinates outer mitochondrial membrane proteins | Central effector; point mutations linked to Parkinson's disease [1,4] |
| NIPA2 | Modulates mitophagy in osteoblasts | Regulates osteoblast function in type 2 diabetes osteoporosis |
| BNIP3 | Mitophagy receptor contributing to cargo recognition | Drives odontoblastic differentiation in dental pulp stem cells |
| GRB2 | Adaptor protein in cardiolipin homeostasis | Mediates ginsenoside Rg3 effects in Parkinson's disease models |
| ATF4 | Transcription factor induced under stress | Cooperates with KPNB1 to induce BNIP3-dependent mitophagy |
| KPNB1 | Nuclear transport factor | Partners with ATF4 in BNIP3-dependent mitophagy |
| LC3 | Autophagosome membrane protein | Docks autophagy receptors on ubiquitinated mitochondria |
| SQSTM1 | Autophagy receptor | Recognizes ubiquitinated mitochondrial cargo |
| OPTN | Autophagy receptor | Links ubiquitinated mitochondria to autophagosomes |
| MFN1 | Mitochondrial fusion protein | PRKN substrate whose ubiquitination promotes fragmentation |
| MFN2 | Mitochondrial fusion protein | PRKN substrate and Parkinson's disease-related gene [1,4] |
| VDAC1 | Outer mitochondrial membrane channel | PRKN substrate and ubiquitination target |
| TOMM20 | Outer mitochondrial membrane translocase | Commonly used marker of mitochondrial mass during mitophagy |
| TIMM23 | Inner mitochondrial membrane translocase | Marker of mitochondrial clearance in mitophagy assays |
| MAP1LC3B | Autophagosome marker | Used to monitor mitophagic flux |
| GAPDH | Glycolytic enzyme | Loading control in mitophagy Western blots |
How Is positive regulation of type 2 mitophagy Regulated?
Positive regulation of type 2 mitophagy is controlled at multiple levels. PINK1 stabilization and PRKN activation are the primary upstream switches, and their activity is modulated by mitochondrial membrane potential. Pharmacological agents such as metformin and ginsenoside Rg3 can influence mitophagic flux in metabolic and neurodegenerative models [4,6]. Mitochondrial biogenesis pathways are coordinately regulated with mitophagy to maintain organelle homeostasis. In disease states, high-fat diet and inflammatory conditions can impair mitophagic flux, effectively reducing positive regulation of type 2 mitophagy [1,3].
positive regulation of type 2 mitophagy and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PINK1 | Periodontitis-induced bone loss | Pink1 knockout mouse osteoclast cultures |
| PRKN | Parkinson's disease | PRKN mutant patient-derived neurons [1,4] |
| NIPA2 | Type 2 diabetes osteoporosis | Nipa2 knockout osteoblast cell line |
| BNIP3 | Odontoblastic differentiation | BNIP3 knockdown dental pulp stem cells |
| GRB2 | Parkinson's disease | GRB2 knockout neuronal cells treated with ginsenoside Rg3 |
Neurodegeneration and Parkinson's disease
Loss of PINK1 or PRKN function causes familial Parkinson's disease, and impaired type 2 mitophagy leads to accumulation of damaged mitochondria in neurons [1,4]. Ginsenoside Rg3 restores mitochondrial cardiolipin homeostasis via GRB2 and prevents Parkinson's disease in experimental models, highlighting the therapeutic potential of enhancing positive regulation of type 2 mitophagy.
Cardiometabolic disease
Mitophagy is essential for maintaining cardiac function during high-fat-diet-induced diabetic cardiomyopathy, and its impairment exacerbates cardiac dysfunction. Pharmacological approaches that stimulate mitochondrial biogenesis and turnover are being explored for cardiometabolic protection.
Bone and inflammatory disorders
PINK1 restrains periodontitis-induced bone loss by preventing osteoclast mitophagy impairment, directly linking positive regulation of type 2 mitophagy to inflammatory bone disease. NIPA2 regulates osteoblast function by modulating mitophagy in type 2 diabetes osteoporosis, indicating that mitophagic control is required for bone homeostasis.
Crosstalk with cell death pathways
Type 2 mitophagy intersects with ferroptosis and pyroptosis networks, and its dysregulation can shift cell fate decisions in disease. Understanding these crosstalk mechanisms is important for designing combination therapies that target mitochondrial quality control.
From positive regulation of type 2 mitophagy-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PINK1 abolish positive regulation of type 2 mitophagy? | PINK1 knockout cell line with mitophagy reporter |
| Does a disease-associated PRKN mutation impair mitophagic flux? | PRKN point-mutation knock-in cells [1,4] |
| Can a candidate gene enhance mitophagy when overexpressed? | Overexpression cell model with LC3 flux assay [1,3] |
| Where does a candidate protein localize during mitophagy? | Tagged knock-in with fluorescent tag |
| Which genes regulate mitophagy in a genome-wide manner? | CRISPR library screening with mitophagy reporter [1,3] |
| Does NIPA2 modulate osteoblast mitophagy? | NIPA2 knockout osteoblast model |
How to Study the positive regulation of type 2 mitophagy Process
| Method | What It Measures | Typical Application |
|---|---|---|
| mt-Keima imaging | Mitochondrial delivery to lysosomes | Live-cell monitoring of type 2 mitophagy |
| mito-QC reporter | Mitophagic flux | High-content screening of regulators |
| Ubiquitin proteomics | PRKN-dependent ubiquitination | Substrate identification |
| Western blot for TOMM20/TIMM23 | Mitochondrial mass | Validation of mitophagy induction |
| LC3 flux assay | Autophagosome formation | Assessment of pathway activation [1,3] |
| CRISPR knockout screen | Gene requirement for mitophagy | Discovery of positive regulators [1,3] |
| CRISPR activation screen | Gene sufficiency for mitophagy | Identification of enhancers |
| Immunofluorescence | Co-localization of mitochondria and lysosomes | Spatial validation of mitophagy [1,5] |
Live-cell imaging of mitophagy reporters
Fluorescent reporters such as mt-Keima or mito-QC allow real-time monitoring of mitochondrial delivery to lysosomes, providing a direct readout of positive regulation of type 2 mitophagy. These assays are compatible with CRISPR knockout and knock-in cell lines to test causal roles of candidate genes [1,3].
Ubiquitin and mitochondrial proteomics
Quantitative proteomics can measure PRKN-dependent ubiquitination of outer mitochondrial membrane proteins and the loss of mitochondrial mass during type 2 mitophagy. This approach identifies substrates and confirms pathway activation in response to depolarization.
Western blotting of mitophagy markers
Immunoblotting for TOMM20, TIMM23, and LC3 is widely used to assess mitochondrial clearance and autophagic flux. Loss of mitochondrial markers with increased LC3 lipidation indicates enhanced positive regulation of type 2 mitophagy [1,3].
CRISPR-based functional genomics
Pooled CRISPR knockout or activation screens coupled to mitophagy reporters enable unbiased discovery of positive regulators of type 2 mitophagy [1,3]. Hits can be validated individually using point-mutation or overexpression models [1,8].
How CRISPR Can Be Used to Study GO:1905091 positive regulation of type 2 mitophagy
Knockout
CRISPR knockout of PINK1, PRKN, or candidate positive regulators abolishes or reduces type 2 mitophagy, providing causal evidence for their role in GO:1905091 [1,8]. Knockout models are essential for distinguishing required genes from correlative markers.
Point Mutation
Point-mutation knock-in of disease-associated variants in PRKN or other genes allows precise testing of whether specific residues are required for positive regulation of type 2 mitophagy [1,4]. This approach links clinical mutations to pathway function.
Knock-in
Tagged knock-in of endogenous genes with fluorescent or affinity tags enables visualization and purification of proteins during type 2 mitophagy without overexpression artifacts. Knock-in reporters can also be used to monitor pathway dynamics in real time.
Overexpression
Overexpression of candidate positive regulators such as PINK1, PRKN, or BNIP3 can enhance type 2 mitophagy and is useful for gain-of-function studies [1,5]. Overexpression models complement knockout data to establish sufficiency.
How EDITGENE Supports positive regulation of type 2 mitophagy Research
Researchers studying positive regulation of type 2 mitophagy-related genes often need to determine whether a candidate gene is causally involved in mitochondrial clearance or merely correlated with it. CRISPR-based models provide the gold-standard functional evidence, and EDITGENE offers a comprehensive suite of services to generate and characterize these models.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of type 2 mitophagy research.
Frequently Asked Questions About positive regulation of type 2 mitophagy
What is GO:1905091 positive regulation of type 2 mitophagy?
GO:1905091 is a Gene Ontology biological process term describing any process that activates or increases the frequency, rate or extent of type 2 mitophagy, the PINK1-PRKN-dependent clearance of depolarized mitochondria.
What genes are involved in positive regulation of type 2 mitophagy?
Key genes include PINK1, PRKN, NIPA2, BNIP3, GRB2, ATF4, KPNB1, and autophagy receptors such as SQSTM1 and OPTN [1,4,5,8].
How is type 2 mitophagy triggered?
It is triggered by loss of mitochondrial membrane potential, which stabilizes PINK1 on the outer mitochondrial membrane and recruits PRKN to ubiquitinate mitochondrial proteins.
What diseases are linked to impaired type 2 mitophagy?
Impaired type 2 mitophagy is linked to Parkinson's disease, diabetic cardiomyopathy, periodontitis-induced bone loss, and type 2 diabetes osteoporosis [1,3,4,8].
How can I study positive regulation of type 2 mitophagy in the lab?
Common methods include mt-Keima or mito-QC reporters, LC3 flux assays, Western blotting for mitochondrial markers, and CRISPR knockout or overexpression models [1,3].
What is the difference between type 1 and type 2 mitophagy?
Type 2 mitophagy specifically refers to PRKN-mediated clearance of depolarized mitochondria, whereas other forms of mitophagy may be PRKN-independent.
Can CRISPR be used to study type 2 mitophagy?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models are widely used to test causal roles of genes in type 2 mitophagy [1,5,8].
What is the role of PINK1 in type 2 mitophagy?
PINK1 accumulates on depolarized mitochondria and activates PRKN, making it a core initiator of positive regulation of type 2 mitophagy.
How does metformin affect mitophagy?
Metformin has been shown to influence mitophagy-related mechanisms in muscle cells under hyperglycemia, as studied in C2C12 cells.
What experimental models are available for type 2 mitophagy research?
Models include knockout cell lines, point-mutation knock-ins, tagged knock-ins, overexpression lines, and CRISPR library screens, all available from EDITGENE [1,3,8].
Conclusion
GO:1905091, positive regulation of type 2 mitophagy, defines the cellular processes that enhance PINK1-PRKN-dependent clearance of damaged mitochondria. This pathway is critical for neuronal, cardiac, and bone health, and its dysregulation contributes to Parkinson's disease, diabetic cardiomyopathy, and osteoporosis [1,3,4,8]. CRISPR-based functional models are indispensable for dissecting the causal roles of individual genes in this process [1,5,8]. EDITGENE provides end-to-end services to accelerate discovery in this field.
References
- 1. Jang JS et al.. 2024. PINK1 restrains periodontitis-induced bone loss by preventing osteoclast mitophagy impairment.. Redox Biol 69:103023 PMID: 38181706
- 2. Valero T. 2014. Mitochondrial biogenesis: pharmacological approaches.. Curr Pharm Des 20(35):5507-9 PMID: 24606795
- 3. Tong M et al.. 2019. Mitophagy Is Essential for Maintaining Cardiac Function During High Fat Diet-Induced Diabetic Cardiomyopathy.. Circ Res 124(9):1360-1371 PMID: 30786833
- 4. Qi LF et al.. 2024. Ginsenoside Rg3 Restores Mitochondrial Cardiolipin Homeostasis via GRB2 to Prevent Parkinson's Disease.. Adv Sci (Weinh) 11(39):e2403058 PMID: 39159293
- 5. Zhang Z et al.. 2024. KPNB1-ATF4 induces BNIP3-dependent mitophagy to drive odontoblastic differentiation in dental pulp stem cells.. Cell Mol Biol Lett 29(1):145 PMID: 39604846
- 6. Machado IF et al.. 2021. miR-378a-3p Participates in Metformin's Mechanism of Action on C2C12 Cells under Hyperglycemia.. Int J Mol Sci 22(2) PMID: 33430391
- 7. Zhao WY et al.. 2026. The Crosstalk Mechanisms Between Ferroptosis and Pyroptosis and Their Applications in Diseases: From Molecular Networks to Clinical Strategies.. J Cell Mol Med 30(8):e71138 PMID: 42014951
- 8. Zhao W et al.. 2020. NIPA2 regulates osteoblast function by modulating mitophagy in type 2 diabetes osteoporosis.. Sci Rep 10(1):3078 PMID: 32080264
